EHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 14.6% based on the discounted cash flow analysis.
| Market cap | $10.50 Billion |
|---|---|
| Enterprise Value | $10.65 Billion |
| Dividend Yield | $0.76 (0.70%) |
| Earnings per Share | $5.62 |
| Beta | 0.58 |
| Outstanding Shares | 99,200,000 |
| P/E Ratio | 17.24 |
|---|---|
| PEG | 60.73 |
| Price to Sales | 1.69 |
| Price to Book Ratio | 3.13 |
| Enterprise Value to Revenue | 1.76 |
| Enterprise Value to EBIT | 11.9 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.08 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4119▼ 170.74% |
|---|---|
| Total Calls | 352,300▲ 1516.06% |
| Total Puts | 145,100▲ 214.07% |
Holdings and activity of institutional investors.
| Ownership % | 96.11%▼ 1.27% |
|---|---|
| Total Invested | $9.31B▼ 10.05% |
| Investors Holding | 585▼ 11.00% |
No data
Controls taxation policy, directly affecting corporate profitability, and has primary jurisdiction over entitlement spending, including Medicare and Medicaid. These federal programs are major revenue sources for hospitals like EHC, making this committee's decisions directly impactful on EHC's financial health and valuation.
Directly allocates discretionary federal spending. Its subcommittees determine the precise funding levels for federal healthcare programs, which are critical revenue sources for hospitals like EHC. Members would possess direct insight into future funding changes impacting the healthcare sector.
Possesses direct regulatory authority over the FDA and NIH, influencing drug approvals and medical research relevant to hospital operations. Crucially, it also regulates labor laws, which are a major cost driver and operational factor for hospitals like EHC.